Patients with inflammatory bowel disease who started a GLP-1 drug for obesity or diabetes did not have a lower risk of their bowel disease flaring, according to a large analysis of United States insurance claims.
The finding, reported by Medscape from a study published online in Clinical Gastroenterology and Hepatology, tests a hypothesis that had gathered real momentum. Obesity has been linked to worse outcomes in Crohn's disease and ulcerative colitis, and laboratory work suggested GLP-1 signaling might calm gut inflammation directly. Several earlier retrospective studies pointed toward benefit.
This one did not find it. Researchers reported that starting semaglutide or tirzepatide alongside existing IBD treatment was not superior to not starting one.
For the substantial number of people who have both conditions, that changes what these drugs should be expected to do. It does not change whether they are appropriate for the reason they were prescribed.
What the Study Did
The analysis used a method called target trial emulation, which applies the design rules of a randomized trial to observational data. Researchers specify eligibility, treatment start, and follow-up in advance, the way a trial protocol would, to reduce some of the biases that make ordinary database studies unreliable.
The team drew on United States claims data from 2018 through 2023 and identified adults with stable inflammatory bowel disease who also had obesity, diabetes, or both. They then compared those who began semaglutide or tirzepatide against those who did not.
Patients were split into two groups reflecting how their bowel disease was being managed. One group was taking 5-aminosalicylates or no IBD-specific therapy at all. The other was on immunomodulators or advanced therapies such as biologics. That split matters, because a benefit might plausibly appear in patients on lighter treatment and disappear in those already on potent immune-modifying drugs.
Neither group showed a reduction in relapse risk. The study was led by Kuan-Hung Yeh of the University of California San Diego and Dhruv Ahuja of Indira Gandhi Hospital in New Delhi. The authors concluded that GLP-1 "initiation was not superior to noninitiation in improving clinical outcomes" in stable patients in remission.
The work was supported by an International Organization for the Study of Inflammatory Bowel Disease operating grant to the corresponding author, who also reported support from the National Institute of Diabetes and Digestive and Kidney Diseases.
What the Study Cannot Tell You
The limitations are substantial, and the authors name them.
This is observational research. Target trial emulation reduces confounding but does not eliminate it. People who start a GLP-1 drug differ from people who do not in ways that claims data cannot capture, including motivation, diet, and how closely they are followed by a gastroenterologist.
The data are billing records, not clinical records. There were no endoscopy results, no fecal calprotectin values, no disease activity scores. Relapse had to be inferred from what was billed, which means a flare managed with a phone call and a short steroid taper may look different in the data than the same flare managed in a clinic.
There is also a misclassification problem specific to these drugs. Some patients counted as non-initiators may have been taking a GLP-1 purchased outside insurance, through cash pay or compounded sources, which would blur the comparison in the direction of finding no difference.
None of this makes the result wrong. It makes it a well-designed observational finding rather than proof, and it means the question remains genuinely open until a randomized trial answers it. No such trial has been completed, in part because patients with IBD were systematically excluded from the pivotal GLP-1 studies.
Why Earlier Studies Pointed the Other Way
Readers who followed this topic earlier in the year may remember more optimistic headlines, and the discrepancy is worth understanding rather than glossing over.
In January, the Crohn's and Colitis Congress featured research linking GLP-1 use to better IBD outcomes, including lower rates of corticosteroid use, hospitalization and intestinal surgery. Those were conference abstracts, which have not been peer reviewed and typically report fewer methodological details than a published paper.
Published syntheses have also leaned positive. A systematic review and meta-analysis found patients with IBD and obesity taking GLP-1 drugs achieved significant weight loss and had lower risks of surgery and hospitalization, while stating plainly that the findings require confirmation in prospective trials. A separate systematic review in Alimentary Pharmacology and Therapeutics reported meaningful weight and metabolic improvement without an apparent increase in flares.
Those earlier studies mostly compared users against non-users without the design safeguards of a trial emulation, and several measured different outcomes, such as surgery and hospitalization rather than relapse. Studies that ask different questions with different methods can reach different answers without either being fraudulent. When a more rigorous design produces a null result, the honest reading is that the earlier signal was weaker than it appeared.
What This Means for Patients Taking These Drugs
The most useful finding for households may be the one that is easy to skip past. The analysis found no increase in safety events either.
That matters because a real worry has circulated among patients with Crohn's disease and ulcerative colitis: that a drug which slows gastric emptying and commonly causes nausea, diarrhea and constipation might aggravate an inflamed bowel or mask a flare. This study did not find that GLP-1 initiation raised the risk of adverse outcomes in people whose IBD was stable.
So the practical translation is narrow and specific. If you have IBD and are taking a GLP-1 drug for diabetes or obesity, this study is not a reason to stop. If you were hoping it would also protect your bowel disease, the evidence does not currently support that expectation, and it should not factor into decisions about your IBD medications.
Nobody with inflammatory bowel disease should reduce or discontinue biologics, immunomodulators or 5-aminosalicylates on the theory that a GLP-1 drug is covering them. Any change to an IBD regimen belongs in a conversation with a gastroenterologist.
Patients should also know that gastrointestinal side effects from GLP-1 drugs and symptoms of an IBD flare can look similar. New or worsening diarrhea, abdominal pain, blood in stool, unintended weight loss beyond what is expected, or fever should be evaluated rather than attributed to the medication.
What Happens Next
The open question is whether a randomized trial in this population is feasible and who would fund it. Until then, treatment guidelines for inflammatory bowel disease are unlikely to change on this evidence, and GLP-1 prescribing in patients with IBD will continue to be driven by metabolic indications.
MedicalDaily will report on any prospective trial results and on any change to society guidance regarding these drugs in IBD.
The confirmed finding is that a claims-based trial emulation found no reduction in IBD relapse and no increase in safety events with semaglutide or tirzepatide. The people most affected are patients who have both IBD and obesity or diabetes. The most reasonable action is to keep taking prescribed IBD therapy and discuss any regimen change with a specialist. The central uncertainty is whether a randomized trial would confirm the null result or find a benefit this design could not detect.
Frequently Asked Questions
What did the study find? That starting semaglutide or tirzepatide did not lower the risk of inflammatory bowel disease relapse in adults with stable IBD who also had obesity or diabetes, and did not raise safety events.
What kind of study was it? A target trial emulation using United States insurance claims from 2018 through 2023. It is observational research designed to mimic a randomized trial, not a randomized trial itself.
Should I stop my GLP-1 drug if I have Crohn's or colitis? No. The study found no increase in safety problems. Any change should be discussed with your prescriber.
Should I change my IBD medication? No. Do not reduce or stop biologics, immunomodulators or 5-aminosalicylates based on this study. Talk to your gastroenterologist.
Why did earlier studies suggest a benefit? Several were conference abstracts that have not been peer reviewed, and published analyses generally compared users to non-users without the design safeguards of a trial emulation.
What are the main limitations? Claims data lack endoscopy and disease activity measures, residual confounding cannot be excluded, and some patients may have used GLP-1 drugs outside insurance and been miscounted.
When would a definitive answer arrive? Only from a randomized controlled trial. None has been completed, partly because patients with IBD were excluded from the pivotal GLP-1 trials.
